Janux Therapeutics, Inc. (NASDAQ: JANX) is considered one of the best small-cap stocks with significant upside potential.
On October 7, Truist Financial initiated coverage of Janux Therapeutics with a Buy rating. The firm assigned a $100 price target to the stock, highlighting the company’s proprietary platforms, TRACTr and TRACIr. Truist Financial emphasized its confidence in these platforms as key drivers of Janux’s growth and value creation.
Investors looking for promising opportunities in the biotech sector may find Janux Therapeutics an attractive option given its innovative technology and positive analyst outlook.
https://www.insidermonkey.com/blog/janux-therapeutics-janx-gets-initiated-with-a-buy-rating-at-truist-financial-1630307/
